GSK plc has agreed to settle 93% of U.S. state court Zantac product liability cases, involving approximately 80,000 cases, for up to $2.2 billion, with an additional $70 million for a qui tam complaint; no admission of liability was made. The settlements are set to be funded from existing resources and will not affect GSK's growth plans.